Symbols / OVID
OVID Chart
About
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral program that behave similarly in phenotypical screens for the treatment of psychosis in people with NSD and LBD; and OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 107.53M |
| Enterprise Value | 95.69M | Income | -35.87M | Sales | 6.61M |
| Book/sh | 0.63 | Cash/sh | 0.36 | Dividend Yield | — |
| Payout | 0.00% | Employees | 23 | IPO | — |
| P/E | — | Forward P/E | -4.07 | PEG | — |
| P/S | 16.27 | P/B | 2.40 | P/C | — |
| EV/EBITDA | -2.48 | EV/Sales | 14.48 | Quick Ratio | 3.77 |
| Current Ratio | 4.24 | Debt/Eq | 30.79 | LT Debt/Eq | — |
| EPS (ttm) | -0.50 | EPS next Y | -0.37 | EPS Growth | — |
| Revenue Growth | -23.70% | Earnings | 2026-03-10 | ROA | -29.33% |
| ROE | -60.06% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -94.87% | Profit Margin | 0.00% | Shs Outstand | 71.21M |
| Shs Float | 54.45M | Short Float | 8.12% | Short Ratio | 3.12 |
| Short Interest | — | 52W High | 2.01 | 52W Low | 0.24 |
| Beta | 0.26 | Avg Volume | 1.61M | Volume | 968.74K |
| Target Price | $4.05 | Recom | Strong_buy | Prev Close | $1.45 |
| Price | $1.51 | Change | 4.14% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.05
Mean price target
2. Current target
$1.51
Latest analyst target
3. DCF / Fair value
$-6.44
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.51
Low
$2.00
High
$7.00
Mean
$4.05
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-22 | init | LifeSci Capital | — → Outperform | $4 |
| 2025-12-22 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2025-12-11 | init | Roth Capital | — → Buy | $3 |
| 2025-11-24 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2025-11-17 | init | Leerink Partners | — → Outperform | $5 |
| 2025-05-27 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2025-03-24 | main | BTIG | Buy → Buy | $4 |
| 2025-03-24 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2025-03-12 | main | Wedbush | Outperform → Outperform | $3 |
| 2025-01-29 | up | Oppenheimer | Perform → Outperform | $4 |
| 2024-12-04 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-09-30 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-08-19 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-07-26 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-07-02 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-06-18 | main | BTIG | Buy → Buy | $5 |
| 2024-06-18 | main | B. Riley Securities | Buy → Buy | $3 |
| 2024-06-18 | main | Citigroup | Neutral → Neutral | $1 |
| 2024-06-18 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
- Aug Breakouts: What is the target price for OVID stock - 2025 Short Interest & Reliable Volume Spike Alerts - baoquankhu1.vn Wed, 25 Feb 2026 03
- Ovid Therapeutics (OVID) Is Up 42.98% in One Week: What You Should Know - Yahoo Finance Mon, 06 Oct 2025 07
- New brain-targeting drug set for tests in Parkinson’s and dementia psychosis - Stock Titan hu, 18 Dec 2025 08
- Ovid Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis Fri, 19 Dec 2025 08
- Roundup: Ovid Therapeutics and Metagenomi Announce 2025 Third Quarter Results and Leadership Updates - Pharmaceutical Executive hu, 13 Nov 2025 08
- Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why - MSN Fri, 03 Oct 2025 07
- Ovid spikes as Wedbush moves to Outperform on lead asset - Seeking Alpha hu, 09 Oct 2025 07
- Ovid Therapeutics Inc. Announces PIPE Financing Agreement Expected to Generate Up to $175 Million in Gross Proceeds - Quiver Quantitative Fri, 03 Oct 2025 07
- Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why - Stocktwits Fri, 03 Oct 2025 07
- Is Ovid Therapeutics (OVID) One of the Best Fast Growing Penny Stocks to Buy According to Analysts? - Finviz Fri, 30 Jan 2026 08
- Ovid Therapeutics (OVID) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance Wed, 12 Nov 2025 08
- B. Riley Lifts Ovid Therapeutics (OVID) PT to $5 on Strong OV329 Phase 1 Data - Yahoo Finance Sun, 26 Oct 2025 07
- 53% GABA inhibition — Ovid's OV329 delivers Phase 1 biomarker proof and favorable safety profile - Stock Titan Fri, 03 Oct 2025 07
- Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance Wed, 13 Aug 2025 07
- Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Yahoo Finance ue, 04 Nov 2025 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 71000 | — | — | LEVIN JEREMY M | Chief Executive Officer | — | 2025-12-15 00:00:00 | D | nan |
| 1 | 1250000 | — | — | TAKEDA PHARMACEUTICAL CO., LTD. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-08 00:00:00 | I | nan |
| 2 | 3902 | — | Sale at price 0.56 per share. | RONA JEFFREY A | Chief Financial Officer | — | 2025-02-26 00:00:00 | D | 2185.0 |
| 3 | 5279 | — | Sale at price 0.56 per share. | ALEXANDER MARGARET A. | President | — | 2025-02-26 00:00:00 | D | 2956.0 |
| 4 | 43750 | — | Stock Award(Grant) at price 0.00 per share. | RONA JEFFREY A | Chief Financial Officer | — | 2025-02-20 00:00:00 | D | — |
| 5 | 43750 | — | Stock Award(Grant) at price 0.00 per share. | ALEXANDER MARGARET A. | President | — | 2025-02-20 00:00:00 | D | — |
| 6 | 6810 | — | Purchase at price 0.73 per share. | ALEXANDER MARGARET A. | President | — | 2025-01-27 00:00:00 | D | 4971.0 |
| 7 | 18248 | — | Purchase at price 2.76 per share. | LEVIN JEREMY M | Chief Executive Officer | — | 2024-03-18 00:00:00 | D | 50364.0 |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.01 |
| NormalizedEBITDA | -64.57M | -60.71M | -54.17M | 124.45M |
| TotalUnusualItems | 3.30M | 2.00M | ||
| TotalUnusualItemsExcludingGoodwill | 3.30M | 2.00M | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -26.43M | -52.34M | -54.17M | 122.83M |
| ReconciledDepreciation | 613.00K | 568.00K | 1.38M | 237.08K |
| EBITDA | -61.27M | -58.71M | -54.17M | 124.45M |
| EBIT | -61.88M | -59.28M | -55.55M | 124.21M |
| NetInterestIncome | 3.90M | 4.90M | ||
| InterestIncome | 3.90M | 4.90M | ||
| NormalizedIncome | -29.73M | -54.34M | -54.17M | 122.83M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -26.43M | -52.34M | -54.17M | 122.83M |
| TotalExpenses | 62.45M | 59.67M | 57.05M | 84.17M |
| TotalOperatingIncomeAsReported | -61.88M | -59.28M | -55.55M | 124.21M |
| DilutedAverageShares | 70.91M | 70.58M | 70.42M | 68.07M |
| BasicAverageShares | 70.91M | 70.58M | 70.42M | 67.48M |
| DilutedEPS | -0.37 | -0.73 | -0.77 | 1.76 |
| BasicEPS | -0.37 | -0.73 | -0.77 | 1.78 |
| DilutedNIAvailtoComStockholders | -26.43M | -52.34M | -54.17M | 119.84M |
| NetIncomeCommonStockholders | -26.43M | -52.34M | -54.17M | 119.84M |
| OtherunderPreferredStockDividend | 0.00 | 0.00 | 3.00M | |
| NetIncome | -26.43M | -52.34M | -54.17M | 122.83M |
| NetIncomeIncludingNoncontrollingInterests | -26.43M | -52.34M | -54.17M | 122.83M |
| NetIncomeContinuousOperations | -26.43M | -52.34M | -54.17M | 122.83M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 1.33M |
| PretaxIncome | -26.43M | -52.34M | -54.17M | 124.16M |
| OtherIncomeExpense | 31.50M | 2.00M | 1.38M | -45.69K |
| OtherNonOperatingIncomeExpenses | 28.20M | 1.38M | -45.69K | |
| GainOnSaleOfSecurity | 3.30M | 2.00M | ||
| NetNonOperatingInterestIncomeExpense | 3.90M | 4.90M | ||
| InterestIncomeNonOperating | 3.90M | 4.90M | ||
| OperatingIncome | -61.88M | -59.28M | -55.55M | 124.21M |
| OperatingExpense | 62.45M | 59.67M | 57.05M | 84.17M |
| ResearchAndDevelopment | 36.77M | 28.59M | 24.62M | 46.94M |
| SellingGeneralAndAdministration | 25.68M | 31.09M | 32.43M | 37.23M |
| GeneralAndAdministrativeExpense | 25.68M | 31.09M | 32.43M | 37.23M |
| OtherGandA | 11.85M | 13.95M | 16.36M | 23.23M |
| SalariesAndWages | 13.84M | 17.13M | 16.07M | 14.01M |
| TotalRevenue | 566.00K | 392.00K | 1.50M | 208.38M |
| OperatingRevenue | 566.00K | 392.00K | 1.50M | 208.38M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 71.01M | 70.69M | 70.47M | 70.36M |
| ShareIssued | 71.01M | 70.69M | 70.47M | 70.36M |
| TotalDebt | 14.76M | 16.00M | 16.54M | 0.00 |
| TangibleBookValue | 68.23M | 87.80M | 132.05M | 179.58M |
| InvestedCapital | 68.23M | 87.80M | 132.27M | 179.75M |
| WorkingCapital | 45.42M | 98.12M | 124.39M | 175.68M |
| NetTangibleAssets | 68.23M | 87.80M | 132.05M | 179.58M |
| CapitalLeaseObligations | 14.76M | 16.00M | 16.54M | 0.00 |
| CommonStockEquity | 68.23M | 87.80M | 132.27M | 179.75M |
| PreferredStockEquity | 1.00 | 1.00 | 1.00 | |
| TotalCapitalization | 68.23M | 87.80M | 132.27M | 179.75M |
| TotalEquityGrossMinorityInterest | 68.23M | 87.80M | 132.27M | 179.75M |
| StockholdersEquity | 68.23M | 87.80M | 132.27M | 179.75M |
| GainsLossesNotAffectingRetainedEarnings | -35.00K | 1.00K | -42.19K | 0.00 |
| OtherEquityAdjustments | -35.00K | 1.00K | -42.19K | |
| RetainedEarnings | -304.30M | -277.87M | -225.53M | -171.36M |
| AdditionalPaidInCapital | 372.49M | 365.59M | 357.77M | 351.03M |
| CapitalStock | 71.00K | 71.00K | 70.47K | 70.36K |
| CommonStock | 71.00K | 71.00K | 70.47K | 70.36K |
| PreferredStock | 0.00 | 0.00 | 1.00 | 1.00 |
| TotalLiabilitiesNetMinorityInterest | 23.94M | 56.23M | 22.99M | 14.80M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 13.42M | 44.76M | 16.00M | 0.00 |
| OtherNonCurrentLiabilities | 30.00M | |||
| DuetoRelatedPartiesNonCurrent | 0.00 | |||
| TradeandOtherPayablesNonCurrent | 0.00 | |||
| NonCurrentDeferredLiabilities | 0.00 | |||
| NonCurrentDeferredRevenue | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 13.42M | 14.76M | 16.00M | 0.00 |
| LongTermCapitalLeaseObligation | 13.42M | 14.76M | 16.00M | 0.00 |
| CurrentLiabilities | 10.52M | 11.47M | 6.99M | 14.80M |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDeferredRevenue | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 1.34M | 1.25M | 533.95K | |
| CurrentCapitalLeaseObligation | 1.34M | 1.25M | 533.95K | 0.00 |
| PayablesAndAccruedExpenses | 9.19M | 10.23M | 6.46M | 14.80M |
| CurrentAccruedExpenses | 6.00M | 6.52M | 4.50M | 7.67M |
| Payables | 3.19M | 3.70M | 1.95M | 7.13M |
| DuetoRelatedPartiesCurrent | 0.00 | |||
| AccountsPayable | 3.19M | 3.70M | 1.95M | 7.13M |
| TotalAssets | 92.17M | 144.03M | 155.27M | 194.54M |
| TotalNonCurrentAssets | 36.23M | 34.43M | 23.89M | 4.07M |
| OtherNonCurrentAssets | 2.02M | 2.14M | 1.97M | 2.03M |
| NonCurrentPrepaidAssets | 96.03K | |||
| InvestmentsAndAdvances | 20.97M | 17.63M | 5.62M | 1.63M |
| LongTermEquityInvestment | 20.97M | 17.63M | 5.62M | 1.63M |
| GoodwillAndOtherIntangibleAssets | 182.97K | 222.10K | 164.09K | |
| NetPPE | 13.23M | 14.66M | 16.07M | 242.76K |
| AccumulatedDepreciation | -1.41M | -1.00M | -581.38K | -262.21K |
| GrossPPE | 14.64M | 15.66M | 16.65M | 504.96K |
| Leases | 306.00K | 306.00K | 306.31K | 0.00 |
| OtherProperties | 14.92M | |||
| MachineryFurnitureEquipment | 1.53M | 1.46M | 1.42M | 504.96K |
| BuildingsAndImprovements | 12.80M | 13.89M | 14.92M | 0.00 |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 55.94M | 109.60M | 131.38M | 190.48M |
| OtherCurrentAssets | 2.87M | 3.76M | 2.38M | 2.68M |
| PrepaidAssets | 2.68M | |||
| Receivables | 0.00 | |||
| DuefromRelatedPartiesCurrent | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 53.08M | 105.83M | 129.00M | 187.80M |
| OtherShortTermInvestments | 26.77M | 78.79M | 84.13M | 0.00 |
| CashAndCashEquivalents | 26.30M | 27.04M | 44.87M | 187.80M |
| CashEquivalents | 25.78M | 24.34M | 42.01M | 187.59M |
| CashFinancial | 522.00K | 2.70M | 2.85M | 205.56K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -56.12M | -45.92M | -56.65M | 118.42M |
| IssuanceOfCapitalStock | 0.00 | |||
| CapitalExpenditure | -161.00K | -137.00K | -1.42M | -189.41K |
| EndCashPosition | 28.23M | 28.97M | 46.80M | 189.73M |
| BeginningCashPosition | 28.97M | 46.80M | 189.73M | 72.03M |
| ChangesInCash | -740.00K | -17.83M | -142.93M | 117.69M |
| FinancingCashFlow | 622.00K | 30.54M | 180.66K | 904.08K |
| CashFlowFromContinuingFinancingActivities | 622.00K | 30.54M | 180.66K | 904.08K |
| NetOtherFinancingCharges | 30.00M | -21.31K | ||
| ProceedsFromStockOptionExercised | 622.00K | 535.00K | 180.66K | 925.40K |
| NetCommonStockIssuance | 0.00 | |||
| CommonStockIssuance | 0.00 | |||
| InvestingCashFlow | 54.59M | -2.58M | -87.88M | -1.82M |
| CashFlowFromContinuingInvestingActivities | 54.59M | -2.58M | -87.88M | -1.82M |
| NetOtherInvestingChanges | 1.00K | -1.00K | -1.00M | |
| NetInvestmentPurchaseAndSale | 54.75M | 7.56M | -82.96M | 0.00 |
| SaleOfInvestment | 128.00M | 120.00M | 90.00M | 0.00 |
| PurchaseOfInvestment | -73.25M | -112.44M | -172.96M | 0.00 |
| NetBusinessPurchaseAndSale | 0.00 | -10.00M | -2.50M | -1.63M |
| PurchaseOfBusiness | 0.00 | -10.00M | -2.50M | -1.63M |
| NetIntangiblesPurchaseAndSale | -90.00K | -97.00K | -194.40K | -5.40K |
| PurchaseOfIntangibles | -194.40K | -5.40K | ||
| NetPPEPurchaseAndSale | -71.00K | -40.00K | -1.22M | -184.01K |
| PurchaseOfPPE | -71.00K | -40.00K | -1.22M | -184.01K |
| OperatingCashFlow | -55.96M | -45.78M | -55.23M | 118.61M |
| CashFlowFromContinuingOperatingActivities | -55.96M | -45.78M | -55.23M | 118.61M |
| ChangeInWorkingCapital | -150.00K | 2.39M | -8.23M | -16.81M |
| ChangeInOtherWorkingCapital | -12.38M | |||
| ChangeInPayablesAndAccruedExpense | -1.05M | 3.77M | -8.34M | -5.09M |
| ChangeInAccruedExpense | -537.00K | 2.02M | -3.17M | -4.36M |
| ChangeInPayable | -512.00K | 1.75M | -5.17M | -729.70K |
| ChangeInAccountPayable | -512.00K | 1.75M | -5.17M | 1.70M |
| ChangeInPrepaidAssets | 899.00K | -1.39M | 109.29K | 517.67K |
| ChangeInReceivables | 0.00 | 141.76K | ||
| OtherNonCashItems | -32.91M | -1.68M | -1.22M | 7.30M |
| StockBasedCompensation | 6.28M | 7.29M | 6.56M | 5.05M |
| UnrealizedGainLossOnInvestmentSecurities | -3.35M | -2.00M | 454.81K | 0.00 |
| DepreciationAmortizationDepletion | 613.00K | 568.00K | 1.38M | 237.08K |
| DepreciationAndAmortization | 613.00K | 568.00K | 1.38M | 237.08K |
| AmortizationCashFlow | 148.76K | 193.33K | ||
| AmortizationOfIntangibles | 148.76K | 193.33K | ||
| Depreciation | 1.45M | 1.19M | 237.08K | |
| NetIncomeFromContinuingOperations | -26.43M | -52.34M | -54.17M | 122.83M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for OVID
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|